KEGG   DRUG: Asparaginase
Entry
D02997                      Drug                                   
Name
Asparaginase (USAN);
L-Asparaginase (JAN);
Asparaginase Erwinia chrysanthemi (USAN);
Asparaginase erwinia chrysanthemi (recombinant)-rywn;
Elspar (TN);
Erwinaze (TN);
Rylaze (TN)
Product
RYLAZE (Jazz Pharmaceuticals)
Source
Escherichia coli [TAX:562] (JAN), Erwinia chrysanthemi [TAX:556] (USAN)
Remark
Therapeutic category: 4291
ATC code: L01XX02
Product: D02997<JP/US>
Efficacy
Antineoplastic, Enzyme (L-asparaginase)
  Disease
Acute lymphoblastic leukemia [DS:H00001 H00002]
Comment
PEG-L-asparaginase
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XX Other antineoplastic agents
     L01XX02 Asparaginase
      D02997  Asparaginase (USAN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Antineoplastics, Other
   Antineoplastics, Miscellaneous
    Asparaginase Erwinia (Recombinant)
     D02997  Asparaginase (USAN)
    Asparaginase Erwinia chrysanthemi
     D02997  Asparaginase (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D02997  Asparaginase (USAN); L-Asparaginase (JAN); Asparaginase Erwinia chrysanthemi (USAN)
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D02997
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D02997
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D02997
Other DBs
CAS: 9015-68-3
PubChem: 17397153
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system